This Clinical Convergence ® activity addresses new developments in the treatment of relapsed/refractory CML with a focus on appropriate therapeutic decision making and monitoring in the second- and third-line setting. The program features a clinical case vignette to engage the learner and facilitate acquisition and integration of new skills and behaviors, as well as a patient encounter to provide unique perspectives on aspects of treatment selection, adherence, monitoring requirements, and adverse event management. A non-certified practice aid is included as a resource for provider-patient discussions on potential side effects.
Upon successful completion of this education activity, participants should be better able to:
Director, Georgia Cancer Center
Cecil F. Whitaker Jr., GRA Eminent Scholar Chair in Cancer
Section of Hematology/Oncology, Department of Medicine
Georgia Cancer Center at Augusta University
Featured RMEI CE Activities